Julia Lipton at Awesome People Ventures gives away up to 50% of GP carry to her broader community of deal finders and supporters through structures like AngelList's Deal Partners, allowing scouts, founders, and operators who source or help on deals to earn upside even without writing checks themselves. She's betting her career on early-stage venture becoming more community-owned and less firm-centric, restructuring her fund around web3 and decentralization themes while bridging web2 and web3 investments through equity plus token warrant structures.

• Deep interest in health optimization and exposing systemic issues in the food supply chain. This is best exemplified by her recent citizen science initiative to crowdfund independent testing of baby formula for contaminants like heavy metals and pesticides, driven by her research into how outdated regulations fail to protect against modern toxins.
• A focus on crowdsourced medical research and decentralized science that bridges the gap between anecdotal evidence and formal studies. She actively proposed building a platform that sits between Reddit and formal clinical trials to track longitudinal outcomes for chronic conditions and expressed a desire to fund tests for off-label uses of FDA-approved drugs.
• Active investment focus on crypto startups with real-world consumer applications and strong go-to-market strategies. She explicitly called for founders with backgrounds from major payment companies like Stripe or Coinbase and highlighted unique crypto use cases, such as the community using a meme coin to raise over a million dollars for rare disease research.
• Attraction to founders disrupting legacy industries with unique insights rather than just traditional industry experience. She describes the current startup environment as a time to dismantle old structures in sectors like healthcare and education, noting that founders with a specific superpower or unseen inflection point can win against incumbent bureaucracy.
• Advocacy for women's health and family-related medical challenges as massive, under-addressed market opportunities. She rejects the notion that women's health is a niche vertical since it concerns half the population and shares personal motivations for tackling neurodegenerative diseases, citing her father's battle with Alzheimer's as a driver for better disease tracking.